Investigating the Application of Liposomes as Drug Delivery Systems for the Diagnosis and Treatment of Cancer

Table 3

An illustration of liposomal products in varying clinical trial phases yet to be approved with their intended clinical application and preferred administration route.

Drug name	Clinical application	Route of administration	Clinical trial phase	Year of approval
Doxorubicin [26, 89–91] (ThermoDox®) (thermosensitive)	Primary hepatocellular carcinoma	Intravenous injection	Phase III	2000
Cisplatin [26, 92, 93] (Lipoplatin^TM)	Non-small cell lung cancer	Intravenous injection	Phase III	2007
BLP25 vaccine [26, 94, 95] (Stimuvax®)	Non-small cell lung cancer	Intravenous injection	Phase III	2006
Paclitaxel [26, 96, 97] (EndoTag®-1) (cationic)	Pancreatic cancer	Intravenous injection	Phase II	2005
L-Annamycin [74, 98]	Refractory acute AML or relapsed AML	Intravenous injection	Phase II	2005
Cisplatin [99] (SPI-77)	Head and neck cancer (Z)/lung cancer	Intravenous injection	Phase II	1998
Lurtotecan [100] (OSI-211)	Head, neck, and ovarian cancer	Intravenous injection	Phase II	2001
L-NDDP [101] (Aroplatin^TM)	Colorectal cancer (metastatic)	Intravenous injection	Phase II	2002
Paclitaxel [102, 103] (LEP-ETU)	Solid tumour cancers	Intravenous infusion	Phase II	2004
Vinorelbine [104] (NanoVNB®)	Solid tumour cancers (advanced)	Intravenous injection	Phase I	2004
Mitoxantrone [74, 105] (LEM-ETU)	Solid tumour cancers (advanced)	Intravenous injection	Phase I	2001
Docetaxel [106] (ATI-1123)	Solid tumour cancers (advanced)	Intravenous injection	Phase I	2009
PKN3 targeting siRNA [107] (Atu027)	Solid tumour cancers (advanced)	Intravenous infusion	Phase I	2009
P53 (gene) [108] (SGT-53)	Solid tumour cancers	Intravenous infusion	Phase I	2008